Nephroblastoma Clinical Trial
— GFANEPHRO20Official title:
Therapeutic Recommendations for the Treatment of Children With Nephroblastoma in Africa.
The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | September 30, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 18 Years |
Eligibility | Inclusion Criteria: Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment. . Exclusion Criteria: Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal |
Country | Name | City | State |
---|---|---|---|
Burkina Faso | Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle | Ouagadougou | |
Congo, The Democratic Republic of the | CUK (Cliniques Universitaires de Kinshasa) | Kinshasa | |
Congo, The Democratic Republic of the | Cliniques Universitaires de Lubumbashi (CUL) | Lubumbashi | |
Côte D'Ivoire | CHU de Treichville à ABIDJAN | Abidjan | |
Madagascar | HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona | Antananarivo | |
Mali | CHU Gabriel Touré (HGT) | Bamako | |
Senegal | Hôpital Aristide Le Dantec, Avenue Pasteur, BP 3001 | Dakar |
Lead Sponsor | Collaborator |
---|---|
French Africa Pediatric Oncology Group |
Burkina Faso, Congo, The Democratic Republic of the, Côte D'Ivoire, Madagascar, Mali, Senegal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of the number of cases with local disease. | By evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis. | 5 years | |
Primary | Evaluation of the number of cases with stage IV disease. | By evaluating the initial clinical reports and later histological reports to confirm the stage. | 5 Years | |
Primary | Evaluating the treatment given. | Comparison of treatment given and recommended treatment. | 5 Years | |
Primary | Evaluating the follow up after treatment. | How many children alive or dead after treatment | 5 Years | |
Secondary | Why has treatment failed | look at precision of reporting by comparing reports (histological and surgical) | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001509 -
A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor
|
Phase 2 | |
Not yet recruiting |
NCT04168788 -
Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL
|
N/A | |
Completed |
NCT05245123 -
Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families
|
||
Recruiting |
NCT05985161 -
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
|
Phase 2 |